
|Articles|May 1, 2003
Corticosteroid shown to be safe for long-term SAC control
Author(s)Charles Slonim, MD, Chet Scerra
Tampa, FL-Loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb Pharmaceuticals and Pharmos Corp.), the first corticosteroid specifically designed for signs and symptoms of seasonal allergic conjunctivitis (SAC), is safe for long-term use, according to a recent multicenter study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
2
AAO 2025: The outcomes of the VERONA and DAVIO-2 studies set up continued phase 3 research
3
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
4
AAO 2025: Arshad M. Khanani, MD, highlights 3-year results from the GATHER2 open-label extension trial
5